Morphological evidence of ototoxicity of the iron chelator deferoxamine

被引:25
|
作者
Ryals, B
Westbrook, E
Schacht, J
机构
[1] MCGUIRE RES INST,RICHMOND,VA
[2] UNIV MICHIGAN,KRESGE HEARING RES INST,ANN ARBOR,MI 48109
关键词
ototoxicity; iron chelator; deferoxamine;
D O I
10.1016/S0378-5955(97)00094-4
中图分类号
R36 [病理学]; R76 [耳鼻咽喉科学];
学科分类号
100104 ; 100213 ;
摘要
Recent reports of the role of iron-catalyzed free radical formation in gentamicin ototoxicity and the successful attenuation of gentamicin ototoxicity by iron chelators led us to re-examine experimental material from a previously unpublished study of deferoxamine. Deferoxamine was injected i.m. into adult Japanese quail at either 300 or 750 mg/kg body weight for 30 days. Examination of sections from the basilar papilla at the light microscope level indicated that supporting cells were damaged after the lower drug dose, and that both supporting cells and hair cells were damaged after the higher drug dose. High, prolonged exposure to deferoxamine produced pathological changes similar to those seen in the basilar papilla after much lower, shorter doses of gentamicin. These results demonstrate that deferoxamine damages the quail inner ear and are consistent with the idea that the ototoxic actions of gentamicin may be mediated by iron chelation.
引用
收藏
页码:44 / 48
页数:5
相关论文
共 50 条
  • [41] TEMPORARY IRON REMOVAL BY CHELATOR DEFEROXAMINE IS AN EFFECTIVE PHYSIOLOGICAL PURGING METHOD FOR THE AUTOLOGOUS MARROW GRAFTS IN ADVANCED NEUROBLASTOMA
    SKALA, JP
    CANNON, W
    ROGERS, PCJ
    FRYER, CJH
    KAVAN, P
    KOBYLKA, P
    HRUBA, A
    KOUTECKY, J
    FASEB JOURNAL, 1995, 9 (06): : A1371 - A1371
  • [42] Effects of the iron chelator, hydroxy-ethyl starch deferoxamine, on nerve conduction and blood flow in diabetic rats
    Cameron, NE
    Cotter, MA
    DIABETES, 1999, 48 : A54 - A54
  • [43] REPERFUSION THERAPY WITH THE IRON CHELATOR DEFEROXAMINE-HYDROXYETHYL STARCH DOES NOT LIMIT CANINE MYOCARDIAL INFARCT SIZE
    LESNEFSKY, EJ
    HEDLUND, BE
    HORWITZ, LD
    CLINICAL RESEARCH, 1990, 38 (01): : A89 - A89
  • [44] ENHANCEMENT OF METHYLENE BLUE-INDUCED CYTOTOXICITY IN HUMAN BRAIN-TUMOR CELLS BY AN IRON CHELATOR, DEFEROXAMINE
    LEE, YS
    HAN, SK
    WURSTER, RD
    ARCHIVES OF PHARMACAL RESEARCH, 1995, 18 (03) : 159 - 163
  • [45] Regression of dilated cardlomyopathy after switching iron chelator from deferoxamine (DFX) to deferiprone (L1)
    Chang, Jeng S.
    Huang, Yu C.
    Wu, Karh H.
    Peng, Ching T.
    Su, Bai H.
    Yeh, Tsu F.
    PEDIATRIC BLOOD & CANCER, 2007, 48 (06) : 608 - 608
  • [46] SYNERGY BETWEEN THE IRON CHELATOR DEFEROXAMINE AND THE ANTI-MICROBIAL AGENTS GENTAMICIN, CHLORAMPHENICOL, CEFALOTHIN, CEFOTIAM AND CEFSULODIN
    VANASBECK, BS
    MARCELIS, JH
    VANKATS, JH
    JAARSMA, EY
    VERHOEF, J
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1983, 2 (05) : 432 - 438
  • [47] Improved cardioprotection with the oral iron-chelator l1, over standard therapy with subcutaneous deferoxamine in iron overload cardiomyopathy
    Anderson, L
    Wonke, B
    Prescott, E
    Holden, S
    Walker, JM
    Pennell, D
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) : 218A - 218A
  • [48] Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry.
    Grosse, Regine
    Janssen, Gisela
    Engelhardt, Rainer
    Groeger, Marketa
    Leismann, Oliver
    Nielsen, Peter
    Fischer, Roland
    Janka, Gritta
    BLOOD, 2006, 108 (11) : 505A - 505A
  • [49] Deferoxamine as a chelator for 67Ga in the preparation of antibody conjugates
    Govindan, SV
    Michel, RB
    Griffiths, GL
    Goldenberg, DM
    Mattes, MJ
    NUCLEAR MEDICINE AND BIOLOGY, 2005, 32 (05) : 513 - 519
  • [50] DEFEROXAMINE AND SWEAT IRON
    APTE, SV
    PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 1967, 125 (01): : 117 - &